Guangzhou LintonPharm

LintonPharm is a clinical-stage biopharmaceutical company headquartered in Guangzhou, China, specializing in the development of next-generation bispecific antibodies for cancer immunotherapy. The company's core technology is the ART-Ig platform, which enables the design of T-cell engaging bispecific antibodies with improved safety and efficacy profiles. Its lead candidate, catumaxomab (LIN001), is a trifunctional bispecific antibody targeting EpCAM and CD3, currently being evaluated in Phase 2/3 trials for malignant ascites and gastric cancer. LintonPharm maintains a global footprint with research and development facilities in China, Germany, and the United States. The company aims to address significant unmet medical needs in oncology through its robust pipeline of multi-specific immune-cell engagers. By leveraging its proprietary technology, LintonPharm is committed to delivering transformative treatments to cancer patients worldwide.